Andreas Jurgeit

Merck Ventures
Gustav Mahlerplein 102
Toyo lto Building, 20th Floor
1082 MA Amsterdam
The Netherlands

Andreas Jurgeit, PhD, joined the Life Science team as Investment Director in April 2016. Andreas previously held positions as Investment Manager at the Zurich-based VC Redalpine, active across various industries with investments in life sciences and ICT, and then led Business Development at the Swiss-based Redbiotec where he was instrumental to the trade-sale of its subsidiary RedVax to Pfizer in 2014. Andreas received his MSc in Molecular Biology from the University of Innsbruck (Austria) and his PhD in Cell Biology and Molecular Virology from the University of Zurich (Switzerland) where he worked with the Menlo Park-based 3V Biosciences on the discovery of host factor-based antiviral strategies and drug development by applying Systems Biology approaches. Andreas lectures on Business Strategy (IFJ, ETH Zurich) and advises academic institutes on the commercialization of research findings. Andreas is based in Amsterdam.

Portfolio Company

more about
Indie molecular